ISIN | LU1477743204 |
---|---|
Valor Number | |
Bloomberg Global ID | |
Fund Name | Bellevue Healthcare Strategy I EUR |
Fund Provider |
Bellevue Asset Management AG
Zürich, Switzerland Phone: +41 44 267 67 00 E-Mail: info@bellevue.ch Web: www.bellevue.ch |
Fund Provider | Bellevue Asset Management AG |
Representative in Switzerland |
Waystone Fund Services (Switzerland) SA Lausanne Phone: 0041213111781 |
Distributor(s) |
Bank am Bellevue AG Küsnacht Phone: +41 44 267 67 67 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | Combination of issuing commission charged by the fund management company and transaction fee charged by the fund |
Redemption Condition | Combination of redemption commission charged by the fund management company and transaction fee charged by the fund |
Investment Strategy *** | The Sub-fund is an actively managed equity fund. It is based on the Bellevue Healthcare Strategy that has been in existence since 2007. The investment objective of the sub-fund is to achieve long-term capital growth by investing at least two-thirds of the net assets of Bellevue Healthcare Strategy in a portfolio of carefully chosen shares and other equity securities of companies in the healthcare industry, or companies whose main activity consists of holding shares in such companies or financing such companies and who have their registered office or carry out the majority of their economic activity in recognised countries. |
Peculiarities |
Current Price * | 252.30 EUR | 07.11.2024 |
---|---|---|
Previous Price * | 251.73 EUR | 06.11.2024 |
52 Week High * | 260.08 EUR | 30.08.2024 |
52 Week Low * | 226.11 EUR | 29.11.2023 |
NAV * | 252.30 EUR | 07.11.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 383,756,168 | |
Unit/Share Assets *** | ||
Trading Information SIX |
YTD Performance | +8.46% |
29.12.2023 - 07.11.2024
29.12.2023 07.11.2024 |
---|---|---|
YTD Performance (in CHF) | +10.10% |
29.12.2023 - 07.11.2024
29.12.2023 07.11.2024 |
1 month | +0.51% |
07.10.2024 - 07.11.2024
07.10.2024 07.11.2024 |
3 months | +3.20% |
07.08.2024 - 07.11.2024
07.08.2024 07.11.2024 |
6 months | +3.47% |
07.05.2024 - 07.11.2024
07.05.2024 07.11.2024 |
1 year | +10.63% |
07.11.2023 - 07.11.2024
07.11.2023 07.11.2024 |
2 years | +1.97% |
07.11.2022 - 07.11.2024
07.11.2022 07.11.2024 |
3 years | -2.09% |
08.11.2021 - 07.11.2024
08.11.2021 07.11.2024 |
5 years | -0.80% |
15.06.2021 - 07.11.2024
15.06.2021 07.11.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Eli Lilly and Co | 3.41% | |
---|---|---|
Regeneron Pharmaceuticals Inc | 3.39% | |
HCA Healthcare Inc | 3.33% | |
Vertex Pharmaceuticals Inc | 3.22% | |
Boston Scientific Corp | 3.07% | |
Insulet Corp | 3.06% | |
UCB SA | 3.03% | |
UnitedHealth Group Inc | 3.00% | |
Stryker Corp | 2.84% | |
IQVIA Holdings Inc | 2.83% | |
Last data update | 31.08.2024 |
TER | 1.55% |
---|---|
TER date | 29.01.2021 |
Performance Fee *** | 0.00% |
PTR | |
Max. Management Fee *** | 0.90% |
Ongoing Charges *** | 1.50% |
SRRI ***
|
|
SRRI date *** | 31.10.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |